Skip to main content


for males ages 18 years and up (full criteria)
at San Francisco, California
study started
estimated completion:



Randomized, phase 2 study to assess the impact of the multi-disciplinary STAND clinic on changes in key metabolic parameters, quality of life, and patient satisfaction among men receiving androgen deprivation therapy for prostate cancer. Standard-of-care therapy will consist of every 3-month visits comprised of review of medical history, toxicity assessment, and lifestyle modification counseling provided by a dietitian and exercise physiologist on an as-needed basis. Men randomized to participate in the multi-disciplinary STAND clinic will have, in addition to every 3-month visits with an individual health care provider, structured and individualized exercise and dietary counseling. A separate non-randomized patient cohort of 20 patients who are receiving concurrent chemohormonal therapy will be enrolled in parallel. The primary hypothesis of the study is that active participation in a multi-disciplinary clinic, as compared to current standard-of-care, will lead to lessened impact of androgen deprivation therapy on metabolic parameters and improved quality of life.

Official Title

A Multidisciplinary Team-Based Approach to Mitigate the Impact of Androgen Deprivation Therapy in Prostate Cancer: a Randomized Phase 2


Prostate Cancer Cancer Supportive Therapy Androgen Deprivation Therapy Prostatic Neoplasms Hormones Prolactin Release-Inhibiting Factors Androgens


You can join if…

Open to males ages 18 years and up

  • Histologic confirmation of adenocarcinoma of the prostate
  • Receiving or planning to receive ADT with LHRH agonist or antagonist
  • Expected duration of ADT at least 12 months from date of study consent
  • Concurrent antiandrogen therapy allowed but not required
  • First dose of LHRH agonist or antagonist no more than 6 months prior to date of study consent
  • Prior/concurrent radiation allowed
  • Other investigational agents in addition to LHRH agonist/antagonist are allowed (e.g.novel anti-androgens, androgen synthesis inhibitors)
  • Prior androgen deprivation therapy allowed, provided there is documented evidence of testosterone recovery to > 150 ng/dL and greater than 12 months duration between last"effective" date of ADT and date of study consent
  • ECOG performance status of 0 - 2
  • Ability to sign written informed consent
  • Willing to attend monthly clinic visits at UCSF

Randomized cohort only:

  • No prior chemotherapy within 12 months of start date of study
  • No planned chemotherapy at least 12 months from study entry

Non-randomized pilot cohort:

  • Concurrent chemotherapy (initiated within 3 months of study entry) or planned chemotherapy within 3 months of study entry

You CAN'T join if...

  • Physically unable or unwilling to participate in recommended exercise programs or travel to UCSF on a monthly basis
  • Presence of permanent pacemaker or implantable medical device (artificial joint prostheses and venous filters are allowed)


  • UCSF Helen Diller Family Comprehensive Cancer Center accepting new patients
    San Francisco, California, 94115, United States


accepting new patients
Start Date
Completion Date
University of California, San Francisco
Phase 2
Lead Scientist
Rahul Aggarwal
Study Type
Last Updated
June 9, 2017
I’m interested in this study!